High‐dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors
Open Access
- 25 January 2008
- Vol. 112 (6), 1345-1353
- https://doi.org/10.1002/cncr.23305
Abstract
BACKGROUND. High-dose chemotherapy (HDCT) with autologous stem cell rescue (ASCR) has been reported to be effective in treating children with recurrent central nervous system (CNS) malignancies. METHODS. To evaluate the efficacy and toxicities of HDCT and ASCR, the medical records of 27 children with recurrent CNS malignancies who received such therapy at St. Jude Children's Research Hospital between 1989 and 2004 were reviewed. RESULTS. The median age at diagnosis was 4.5 years (range, 0.4–16.6 years) and that at ASCR was 6.7 years (range, 1.1–18.5 years). Diagnoses included medulloblastoma (13 patients), primitive neuroectodermal tumor (3 patients), pineoblastoma (2 patients), atypical teratoid rhabdoid tumor (2 patients), ependymoma (3 patients), anaplastic astrocytoma (2 patients), and glioblastoma multiforme (2 patients). The 5-year overall and progression-free survival (PFS) rates were 28.2% and 18.5%, respectively. The 5-year PFS rate for patients aged P = .019). Among the 6 long-term survivors (5 with M0 disease and 1 with M3 disease at diagnosis), 5 received both radiotherapy and HDCT as part of their salvage regimen; 4 were aged <3 years at diagnosis and had received chemotherapy only as part of frontline therapy. Two patients died of transplant-related toxicities; 44% experienced grade 3 or 4 transplant-related toxicities (toxicities were graded according to the National Cancer Institute Common Toxicity Criteria). CONCLUSIONS. HDCT with ASCR is not an effective salvage strategy for older children with recurrent CNS malignancies. The significantly better outcome in the younger cohort was most likely related to the use of radiotherapy as part of the salvage strategy. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 38 references indexed in Scilit:
- Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJournal of Clinical Oncology, 2006
- Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly Occurring Toxicity That May Influence Academic and Social DevelopmentJournal of Clinical Oncology, 2005
- Phase II study of high‐dose chemotherapy before radiation in children with newly diagnosed high‐grade astrocytomaCancer, 2005
- Intellectual and Functional Outcome of Children 3 Years Old or Younger Who Have CNS MalignanciesJournal of Clinical Oncology, 2005
- High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacyBone Marrow Transplantation, 2005
- Evolving role of myeloablative chemotherapy in the treatment of childhood brain tumoursBone Marrow Transplantation, 2005
- High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Children and Adults With Newly Diagnosed PineoblastomasJournal of Clinical Oncology, 2003
- High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumorsBone Marrow Transplantation, 2000
- Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomasEuropean Journal Of Cancer, 1997
- A High-Dose Busulfan-Thiotepa Combination Followed by Autologous Bone Marrow Transplantation in Childhood Recurrent EpendymomaPediatric Neurosurgery, 1996